We expect investors to focus on the sales performance of ADMA Biologics, Inc.’s (ADMA) portfolio of its three marketed commercial products and other pipeline updates when it reports first-quarter 2024 results.Let’s see how things have shaped up for the quarter to be reported.Factors at PlayADMA Biologics markets plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases. The company’s top line currently comprises sales of three FDA-approved products, ...